

ANALGESICS, OPIOID SHORT-ACTING PRIOR AUTHORIZATION FORM

(form effective 7/10/23)



Fax to PerformRxSM at **1-855-851-4058**, or to speak to a representative, call **1-888-674-8720**.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	# of pages:	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	Formulation (capsule, tablet, etc.):
Directions:		Weight (if <21 years of age):
Quantity per fill: _____ to last _____ days	Requested duration:	
Diagnosis (<i>submit documentation</i>):	Dx code (<i>required</i>):	

- **Pennsylvania law requires prescribers to query the PA PDMP each time a patient is prescribed an opioid drug product or benzodiazepine.**
- **Naloxone is available at Pennsylvania pharmacies via standing order from the Secretary of the Department of Health. Pennsylvania Medical Assistance beneficiaries may obtain naloxone free-of-charge through their prescription drug benefit.**

**Complete all sections that apply to the beneficiary and this request.
Check all that apply and submit documentation for each item.**

INITIAL requests

1. For a transmucosal fentanyl product:
 - Has a diagnosis of cancer
 - Is opioid-tolerant (opioid-tolerant is defined as taking at least morphine 60 mg/day, transdermal fentanyl 25 mcg/hour, oxycodone 30 mg/day, oral hydromorphone 8 mg/day, or an equianalgesic dose of another opioid for one week or longer)
 - Is prescribed transmucosal fentanyl by a specialist certified in pain medicine, oncology, or hospice and palliative medicine
 - Has a contraindication to the preferred Analgesics, Opioid Short-Acting (*See the Preferred Drug List for the list of preferred Analgesics, Opioid Short-Acting at: <https://papdl.com/preferred-drug-list>*)
2. For nasal butorphanol:
 - Is **not** opioid-tolerant (opioid-tolerant is defined as taking at least morphine 60 mg/day, transdermal fentanyl 25 mcg/hour, oxycodone 30 mg/day, oral hydromorphone 8 mg/day, or an equianalgesic dose of another opioid for one week or longer)
 - Is being treated for **migraine** and:
 - Is prescribed nasal butorphanol by a neurologist or headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties
 - Tried and failed or has a contraindication or an intolerance to the following abortive medications:
 - acetaminophen
 - NSAIDs
 - triptans
 - dihydroergotamine
 - Tried and failed or has a contraindication or an intolerance to the following preventive medications:
 - anticonvulsants
 - beta blockers
 - botulinum toxins
 - CGRP inhibitors
 - calcium channel blockers
 - SNRIs
 - tricyclic antidepressants
 - Is being treated for **non-migraine pain** and:
 - Is prescribed nasal butorphanol by a specialist certified in neurology, pain medicine, oncology, or hospice and palliative care medicine
 - Tried and failed or has a contraindication or intolerance to **at least 3** unrelated (i.e., different opioid ingredient) preferred Analgesics, Opioid Short-Acting (*See the Preferred Drug List for the list of preferred Analgesics, Opioid Short-Acting at: <https://papdl.com/preferred-drug-list>*)
 - List preferred medications tried: _____
3. For a **non-preferred Analgesic, Opioid Short-Acting** (*See the Preferred Drug List for the list of preferred and non-preferred Analgesics, Opioid Short-Acting at: <https://papdl.com/preferred-drug-list>*):
 - Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Short-Acting
 - List preferred medications tried: _____
4. For a beneficiary with a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder (OUD) OR Vivitrol (naltrexone extended-release suspension for injection):
 - Both prescriptions are prescribed by the same prescriber
 - Prescriptions are prescribed by different prescribers and all prescribers are aware of the other prescription(s)
 - Not applicable — beneficiary is not taking a buprenorphine agent indicated for the treatment of OUD or Vivitrol

ANALGESICS, OPIOID SHORT-ACTING PRIOR AUTHORIZATION FORM

INITIAL requests (continued)

5. For all Analgesics, Opioid Short-Acting:

- Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome
- Is receiving palliative care or hospice services
- Is receiving treatment post-operatively or following a traumatic injury
- Has documentation of pain that is all of the following:
 - Caused by a medical condition
 - Not migraine in type
 - Moderate to severe
- Tried and failed or has a contraindication or an intolerance to non-opioid analgesics appropriate for the beneficiary's condition:
 - acetaminophen
 - duloxetine (e.g., Cymbalta, Drizalma)
 - gabapentinoids (e.g., gabapentin, pregabalin [Lyrica])
 - NSAIDs (e.g., ibuprofen, naproxen, meloxicam, etc.)
 - tricyclic antidepressants (e.g., amitriptyline, nortriptyline, etc.)
 - other (specify): _____
- Was assessed for the potential risk of opioid misuse or opioid use disorder by the prescriber

6. For a beneficiary with a concurrent prescription for a benzodiazepine:

- The benzodiazepine is being tapered
- The opioid is being tapered
- Concomitant use of the benzodiazepine and opioid is medically necessary
- Not applicable — beneficiary is not taking a benzodiazepine

7. For a beneficiary who has received opioid treatment for the past 3 months:

- Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abuse, including specific testing for oxycodone, fentanyl, buprenorphine, and tramadol, that is consistent with prescribed controlled substances

RENEWAL requests

1. For all Analgesics, Opioid-Short Acting:

- Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome
- Is receiving palliative care or hospice services
- Experienced an improvement in pain control and/or level of functioning while on the requested medication
- Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abuse, including specific testing for oxycodone, fentanyl, buprenorphine, and tramadol, at least every 12 months that is consistent with prescribed controlled substances

2. For a beneficiary with a concurrent prescription for a benzodiazepine:

- The benzodiazepine is being tapered
- The opioid is being tapered
- Concomitant use of the benzodiazepine and opioid is medically necessary
- Not applicable — beneficiary is not taking a benzodiazepine

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.